RxDoctor Payments DataLook up a doctor →

Jamal Hammoud, MD

Endocrinology, Diabetes & Metabolism · Flint, MINPI 1639284672

Payments from drug & device makers

$2,577,361in general payments, 2019–2025

Across 3,149 payments — averaging $818.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$635K
  • Sanofi US Services Inc.$501K
  • Novo Nordisk AS$361K
  • AstraZeneca$271K
  • Lilly USA, LLC$233K
  • AbbVie$232K
  • plus $344K from 54 others
$1,994in research payments, 2019–2025

Across 2 payments — averaging $997.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim159$634,954
Sanofi US Services Inc.70$501,025
Novo Nordisk AS1,044$361,420
AstraZeneca(2 entities)108$270,661
Lilly USA, LLC387$232,551
AbbVie66$232,134
Bayer57$104,958
Lexicon Pharmaceuticals, Inc.2$49,637
Gilead28$45,020
Boehringer Ingelheim International GmbH116$27,871
Sanofi-aventis U.S. LLC74$21,641
Janssen Research & Development, LLC1$20,563
Novo Nordisk226$18,981
Johnson & Johnson30$15,158
Pfizer8$11,659
Boehringer Ingelheim Pharma GmbH & Co.kg3$10,015
Merck36$5,149
Medtronic(2 entities)70$3,702
Corcept Therapeutics122$1,688
Amgen(2 entities)120$1,515
Xeris Pharmaceuticals, Inc.74$1,102
Dexcom, Inc.58$967
Abbott68$959
Antares Pharma, Inc.24$412
Amneal Pharmaceuticals LLC18$321
Insulet Corporation18$294
BETA Bionics, Inc.19$284
Radius Health, Inc.16$283
Recordati_rare_diseases_inc.10$227
Mannkind Corporation13$202
IBSA Pharma Inc.14$201
Tandem Diabetes Care, Inc.9$163
Ascendis Pharma Endocrinology Inc7$149
Neurocrine Biosciences, Inc.5$123
Shire North American Group Inc5$98
Ultragenyx Pharmaceutical Inc.5$97
Madrigal Pharmaceuticals4$88
Alvogen Inc5$85
Takeda Pharmaceuticals U.S.A., Inc.3$75
Cequr Corporation2$70
Nevro Corp.2$70
Amarin Pharma, Inc.4$61
BD4$59
Teleflex LLC1$54
Embecta Corp.3$48
Verity Pharmaceuticals Inc.2$46
Lifescan, Inc.2$44
EUSA Pharma (US) LLC2$38
GSK2$36
Sanofi1$32
Acella Pharmaceuticals, LLC2$31
Clarus Therapeutics Inc.2$29
Novartis1$28
Kyowa Kirin, Inc.1$25
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$24
Ipsen Biopharmaceuticals, Inc1$22
Amphastar Pharmaceuticals, Inc.1$21
Amryt Pharma Holdings Ltd1$20
Halozyme Inc1$20
Vivus LLC1$18

How this compares

$2,577,361 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024
$285,122
Medicare patients
738
Services billed
4,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Flint

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →